Verastem Inc (VSTM)
2.93
-0.32
(-9.85%)
USD |
NASDAQ |
Jul 02, 16:00
2.99
+0.06
(+2.05%)
After-Hours: 16:57
Verastem Research and Development Expense (TTM): 67.05M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 67.05M |
| December 31, 2023 | 61.36M |
| September 30, 2023 | 49.59M |
| June 30, 2023 | 46.94M |
| March 31, 2023 | 48.93M |
| December 31, 2022 | 50.56M |
| September 30, 2022 | 51.21M |
| June 30, 2022 | 49.25M |
| March 31, 2022 | 44.09M |
| December 31, 2021 | 39.35M |
| September 30, 2021 | 38.10M |
| June 30, 2021 | 39.73M |
| March 31, 2021 | 39.35M |
| December 31, 2020 | 41.38M |
| September 30, 2020 | 43.68M |
| June 30, 2020 | 44.94M |
| March 31, 2020 | 46.94M |
| December 31, 2019 | 45.78M |
| September 30, 2019 | 42.08M |
| June 30, 2019 | 41.44M |
| March 31, 2019 | 42.47M |
| December 31, 2018 | 43.65M |
| September 30, 2018 | 46.14M |
| June 30, 2018 | 52.31M |
| March 31, 2018 | 48.97M |
| Date | Value |
|---|---|
| December 31, 2017 | 46.42M |
| September 30, 2017 | 42.06M |
| June 30, 2017 | 28.54M |
| March 31, 2017 | 23.98M |
| December 31, 2016 | 19.78M |
| September 30, 2016 | 20.58M |
| June 30, 2016 | 27.66M |
| March 31, 2016 | 34.22M |
| December 31, 2015 | 40.56M |
| September 30, 2015 | 42.56M |
| June 30, 2015 | 40.30M |
| March 31, 2015 | 37.56M |
| December 31, 2014 | 35.45M |
| September 30, 2014 | 33.56M |
| June 30, 2014 | 31.30M |
| March 31, 2014 | 29.04M |
| December 31, 2013 | 25.93M |
| September 30, 2013 | 22.22M |
| June 30, 2013 | 23.57M |
| March 31, 2013 | 22.20M |
| December 31, 2012 | 21.71M |
| September 30, 2012 | 22.02M |
| June 30, 2012 | 16.97M |
| March 31, 2012 | 14.01M |
| December 31, 2011 | 9.883M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
38.10M
Minimum
Sep 2021
67.05M
Maximum
Mar 2024
46.86M
Average
45.78M
Median
Dec 2019
Research and Development Expense (TTM) Benchmarks
| Assertio Holdings Inc | 3.576M |
| Nektar Therapeutics | 111.10M |
| Cara Therapeutics Inc | 106.14M |
| Ocugen Inc | 36.84M |
| NovaBay Pharmaceuticals Inc | 0.061M |